Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax®
Marc Mansour(Leidos (United States)), Pirouz Daftarian(University of Miami), Genevieve Weir(Immunovaccine (Canada)), W. Martin Kast(University of Southern California), Ella Korets-Smith(Immunovaccine (Canada)), Bill Pohajdak(Immunovaccine (Canada)), Antar Fuentes-Ortega(Immunovaccine (Canada)), Robert G. Brown(Nuffield Orthopaedic Centre)
Cited by 49
Related Papers
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.
|The Journal of Immunology|1994|851
Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
|European Journal of Immunology|1993|840
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis
|Nature Medicine|2011|834
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells
|Nature Medicine|2002|549